Business Management Articles

ASCO 2017: Same-Day Dosing Cuts Costs

Researchers achieved cost savings and cut down on the amount of drug they had to throw away by pooling drug vials and dosing all patients with a given disease on the same day of the week, according to data released ahead of the 2017 ASCO Annual Meeting.
FDA Grants Nivolumab Priority Review for Liver Cancer
The FDA has granted a priority review designation to nivolumab (Opdivo) for use as a treatment for patients with hepatocellular carcinoma following prior sorafenib (Nexavar).
Weaving Through the Landscape of HER2-Positive Breast Cancer
Adam M. Brufsky, MD, PhD, discusses neratinib, overcoming resistance to HER2-targeted therapy, and the impact of newer agents in HER2-positive breast cancer.
ASCO 2017: Improving the Patient-Doctor Immunotherapy Discussion
Ahead of this year's meeting, researchers are increasingly interested in the state of communication between patients and doctors on immunotherapy. 
A Boot Camp Opens for Oncology Financial Navigators
Clara N. Lambert and the Association of Community Cancer Centers have created an online course called Financial Advocacy Boot Camp, which is designed to give experienced and novice financial navigators a review of essential knowledge for finding patient funds.
Affordable Care Act Positively Affects Stage at Diagnosis
More Stage I cancers were diagnosed after the passage of the Affordable Care Act within five screenable disease types than were diagnosed before ACA implementation.
FDA Grants Priority Review to Copanlisib for Follicular Lymphoma
The FDA has granted a priority review designation to copanlisib as a treatment for patients with relapsed/refractory follicular lymphoma who have received at 2 least prior therapies, according to Bayer, the manufacturer of the PI3K dual-isoform inhibitor.
Reduce Costs By Using Less Radiotherapy
Radiation therapy remains fertile for continued technological innovation that can improve patient outcomes, but of the newest technologies may be practical for only the largest institutions.
Atezolizumab missed the phase III IMvigor211 trial’s primary endpoint of improving overall survival in the second-line setting for patients with locally advanced or metastatic urothelial carcinoma.
Practices Rush to Prepare for USP <800>
Terra Universal, an environmental solutions company based in Fullerton, California, came to a point recently where it was no longer willing to sell and design clean-room setups for oncology practices unless potential clients first sat down with a consultant who could give them reliable guidance on what they needed.
Publication Bottom Border
Border Publication